Indacaterol 150 μg

DRUG8 trials

Sponsors

Novartis, Novartis Pharmaceuticals, AstraZeneca

Conditions

AsthmaChronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary Disease (COPD)

Phase 1

Two-part Pharmacokinetic and Pharmacodynamic Study of LAS190792 in Patients With Asthma and COPD

CompletedNCT02059434

AstraZenecaAsthma, Chronic Obstructive Pulmonary Disease (COPD)

Start: 2013-09-01End: 2014-10-06Updated: 2019-06-21

Phase 2

Dose Ranging Study of Indacaterol in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT00403845

NovartisChronic Obstructive Pulmonary Disease

Start: 2006-12-31End: 2007-10-31Updated: 2011-08-17

Phase 3

Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Using Salmeterol as Active Control

CompletedNCT00567996

NovartisChronic Obstructive Pulmonary Disease (COPD)

Start: 2007-11-30Updated: 2011-08-18

Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT00624286

NovartisChronic Obstructive Pulmonary Disease

Start: 2008-02-29End: 2008-07-31Updated: 2011-08-18

Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease

CompletedNCT00846586

Novartis PharmaceuticalsChronic Obstructive Pulmonary Disease (COPD)

Start: 2009-03-31End: 2010-03-31Updated: 2011-08-18

Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease

CompletedNCT00877383

Novartis PharmaceuticalsChronic Obstructive Pulmonary Disease (COPD)

Start: 2009-04-30End: 2010-02-28Updated: 2011-08-25

A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT00900731

Novartis PharmaceuticalsChronic Obstructive Pulmonary Disease

Start: 2009-06-30End: 2010-03-31Updated: 2011-08-19

Comparison of the Effects of Indacaterol and Tiotropium on Inspiratory Capacity

CompletedNCT00999908

Novartis PharmaceuticalsChronic Obstructive Pulmonary Disease

Start: 2009-10-31End: 2010-03-31Updated: 2016-02-17

Related Papers

Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysis

UNC Libraries2019-08-18

Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison.

2012-04-27113 citations

Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysis.

2011-12-2963 citations

Acute effects of indacaterol on lung hyperinflation in moderate COPD: a comparison with tiotropium.

2011-10-2723 citations

Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD.

2011-03-1125 citations

Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD.

2011-01-1153 citations

Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study.

2010-03-0888 citations